

**Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma - Lymphoma and Myeloma  
Journal Club - 1/15/2025  
1/15/2025 12:00:00 PM - 1/15/2025 1:00:00 PM**

By texting in your attendance, you will be awarded the maximum number of CE credits. If you wish to claim less than the maximum CE credits, please contact [MDAnderson-CPE@mdanderson.org](mailto:MDAnderson-CPE@mdanderson.org)

**Target Audience:**

Professions: Physician Associate, Nurse - APRN

**Learning Objectives:**

- 1 Assess the disease management and toxicities in lymphoma and plasma cell dyscrasias.
- 2 Contribute ones insights and encourage collaborative problem-solving to ensure a comprehensive approach to patient care.
- 3 Utilize journal article discussion on the latest advances in lymphoma and plasma cell dyscrasias to share expertise and understanding between professions.

**Accreditation:**



In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Credit Designation:**

The University of Texas MD Anderson Cancer Center designates this live activity will award 1.00 Nursing Contact Hour(s)



The University of Texas MD Anderson Cancer Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria.

This activity is designated for 1.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

**Commercial Support:**

No commercial support has been received for this activity.

**Disclosure of Financial Relationships:**

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

**Faculty & Planner Disclosure:**

| <b>Name of individual</b>                                | <b>Individual's role in activity</b> | <b>Nature of Relationship(s) / Name of Ineligible Company(s)</b>                                                                                                                                                                                                                                            |
|----------------------------------------------------------|--------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Monica Cummins, Nurse - RN, Family Nurse Practitioner    | Faculty                              | Nothing to disclose - 08/23/2024                                                                                                                                                                                                                                                                            |
| Tiffany Richards, PhD, AN-BC, AOCNP                      | Activity Director                    | Membership on Advisory Committees or Review Panels, Board Membership, etc.- Bristol-Myers Squibb Company   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer Inc.   Membership on Advisory Committees or Review Panels, Board Membership, etc.-GlaxoSmithKline - 04/09/2024 |
| Inez A Serrano, Physician Assistant, Physician Assistant | Activity Co-Director                 | Nothing to disclose - 02/23/2024                                                                                                                                                                                                                                                                            |
| Christy Allen, MPA                                       | Other Planning Committee Member      | Nothing to disclose - 09/10/2024                                                                                                                                                                                                                                                                            |